IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Kitov Pharmaceuticals Holdings Ltd. (“Kitov” or the “Company”) (Nasdaq: KTOV). Investors who purchased or otherwise acquired Kitov shares between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 10, 2017 lead plaintiff deadline.
If you purchased shares of Kitov during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On February 6, 2017, the Israeli publication Calcalist disclosed that Kitov’s Chief Executive Officer, Isaac Israel, had been detained by the Israeli Securities Authority due to allegations of publishing misleading information regarding a recent clinical trial of one of Kitov’s products. When this information was announced to the public, the value of Kitov stock fell, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.